Literature DB >> 7777790

Early clinical experience with a hybrid bioartificial liver.

A A Demetriou1, J Rozga, L Podesta, E Lepage, E Morsiani, A D Moscioni, A Hoffman, M McGrath, L Kong, H Rosen.   

Abstract

BACKGROUND: Severe liver failure is associated with high mortality. Orthotopic liver transplantation (OLT) is the only effective therapeutic modality; there is a need for a 'bridge' system to support patients until an organ becomes available.
METHODS: A bioartificial liver (BAL) was used to treat 10 patients with severe liver failure. A plasmapheresis system was used to pump patient plasma through a module with porcine hepatocytes. Each treatment lasted 6-7 h.
RESULTS: All patients tolerated the procedure(s) well. Eight patients underwent OLT following BAL treatment(s). There were two late deaths after recovery from liver failure. Five patients with increased intracranial pressure (ICP) and decerebration had ICP normalization, increased cerebral perfusion pressure and full neurologic recovery after OLT. There was improvement in the level of encephalopathy and a significant decrease in serum ammonia after BAL treatment(s).
CONCLUSIONS: BAL treatment is safe and beneficial and can be successfully used as a 'bridge' to transplantation.

Entities:  

Mesh:

Year:  1995        PMID: 7777790     DOI: 10.3109/00365529509107771

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  14 in total

1.  Cultivation of human liver cell lines with microcarriers acting as biological materials of bioartificial liver.

Authors:  Yi Gao; Xiao-Ping Xu; Huan-Zhang Hu; Ji-Zhen Yang
Journal:  World J Gastroenterol       Date:  1999-06       Impact factor: 5.742

2.  Artificial and bioartificial liver support.

Authors:  Gesine Pless
Journal:  Organogenesis       Date:  2007-01       Impact factor: 2.500

Review 3.  Cell-based therapy of acute liver failure: the extracorporeal bioartificial liver.

Authors:  B Frémond; A Joly; M Desille; J F Desjardins; J P Campion; B Clément
Journal:  Cell Biol Toxicol       Date:  1996-12       Impact factor: 6.691

4.  Clinical experience with a bioartificial liver in the treatment of severe liver failure. A phase I clinical trial.

Authors:  F D Watanabe; C J Mullon; W R Hewitt; N Arkadopoulos; E Kahaku; S Eguchi; T Khalili; W Arnaout; C R Shackleton; J Rozga; B Solomon; A A Demetriou
Journal:  Ann Surg       Date:  1997-05       Impact factor: 12.969

Review 5.  Is there a future for liver-assist devices?

Authors:  P Rosenthal
Journal:  Curr Gastroenterol Rep       Date:  2000-02

6.  Effects of a bioartificial liver support system on acetaminophen induced acute liver failure canines.

Authors:  Yi-Long Xue; Shi-Feng Zhao; Zuo-Yun Zhang; Yue-Feng Wang; Xin-Jian Li; Xiao-Qiang Huang; Yun Luo; Ying-Cai Huang; Cheng-Gui Liu
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

7.  Experimental study of bioartificial liver with cultured human liver cells.

Authors:  Ying-Jie Wang; Meng-Dong Li; Yu-Ming Wang; Qing-He Nie; Guo-Zheng Chen
Journal:  World J Gastroenterol       Date:  1999-04       Impact factor: 5.742

8.  Systematic review: extracorporeal bio-artificial liver-support system for liver failure.

Authors:  Jinyang Gu; Xiaolei Shi; Haozhen Ren; Qingxiang Xu; Jun Wang; Jiangqiang Xiao; Yitao Ding
Journal:  Hepatol Int       Date:  2012-03-28       Impact factor: 6.047

9.  Stimulation of liver functions in hierarchical co-culture of bone marrow cells and hepatocytes.

Authors:  K Yagi; N Sumiyoshi; Y Nakashima; N Michibayashi; M Kawase; Y Miura; T Mizoguchi
Journal:  Cytotechnology       Date:  1998-01       Impact factor: 2.058

Review 10.  Clinical application of bioartificial liver support systems.

Authors:  Maarten Paul van de Kerkhove; Ruurdtje Hoekstra; Robert A F M Chamuleau; Thomas M van Gulik
Journal:  Ann Surg       Date:  2004-08       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.